Home > Cardiology > ACC/WCC 2020 > Interventional Cardiology > 2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis

2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis

Presented By
Prof. M. Mack, Baylor Scott & White Heart Hospital, USA
Conference
ACC 2020
Trial
PARTNER 3
In a defined population of severe symptomatic aortic stenosis patients who were at low surgical risk, transcatheter aortic valve replacement (TAVR) compared with surgery showed a reduction in death, stroke, or cardiovascular (CV) rehospitalisation at 2 years. Between 1 and 2 years, however, TAVR patients experienced more stroke/death events, which resulted in no significant differences between both groups [1]. Prof. Michael Mack (Baylor Scott & White Heart Hospital, USA) presented the 2-year clinical and echocardiographic outcomes of the PARTNER 3 trial for low-risk patients with severe symptomatic aortic stenosis who were treated with the SAPIEN 3 TAVR system compared with surgery. A thousand patients were randomised 1:1 to TAVR and surgery; follow-up was done at 30 days, 6 months, and continuing annually through 10 years. The primary endpoint was ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on